Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Cardiovascular is a major cause of mortality in Iran, accounting for 45.7% of deaths. In Golestan (North Eastern Iran) preliminary findings from follow-up of the Golestan Cohort are consistent with national figures: with 45% (at least 22 of 48 deaths) of all deaths attributed to cardiovascular events. Cardiovascular diseases will become an increasing problem as the Iranian population ages.
In 2003 Law and Wald proposed prevention of cardiovascular disease using fixed-dose combination therapy combining antihypertensive, lipid lowering and antiplatelet drugs in a single preparation. They proposed that this treatment should be offered to all persons at high risk of cardiovascular disease whether or not they have elevated blood pressure or elevated serum lipid concentrations.
This pilot study aims to investigate the safety and efficacy of fixed-dose combination therapy with two antihypertensive drugs, aspirin and atorvastatin in a population who would not currently be considered eligible for antihypertensive treatment or for lipid lowering treatment.
Methods:
This is a double-blind randomized controlled trial. The intervention group will be assigned to take a tablet consisting of a single daily tablet comprising Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg. The control group will be assigned to an identical placebo.
The population studied includes men aged 50 to 80 (inclusive) and women aged 55 to 80 (inclusive) who are currently not eligible for or taking antihypertensive or lipid lowering therapy. Persons who are found at baseline to have blood pressure >160/100 mm Hg, total cholesterol >240mg/dL, existing cardiovascular disease or to be taking antihypertensive ore lipid lowering therapy are excluded.
It is intended to randomize and follow up 500 subjects for 12 months. The primary outcome for the purpose of sample size calculation is change in systolic blood pressure. Additional outcomes include change in diastolic blood pressure, change in LDL cholesterol and occurrence of adverse events.
| Condition | Intervention | Phase |
|---|---|---|
|
Cardiovascular Disease Hypertension Hyperlipidemia Heart Disease |
Drug: Polypill Drug: Placebo drug |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Phase II Study of Heart Polypill in Primary Prevention of Cardiovascular Disease - Safety and Efficacy |
- Systolic Blood Pressure [ Time Frame: One year ] [ Designated as safety issue: No ]
- Diastolic Blood Pressure [ Time Frame: One year ] [ Designated as safety issue: No ]
- LDL Cholesterol [ Time Frame: One year ] [ Designated as safety issue: No ]
| Enrollment: | 475 |
| Study Start Date: | November 2006 |
| Study Completion Date: | July 2008 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Polypill
Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg
|
Drug: Polypill
Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
|
|
Placebo Comparator: Control
Identical placebo
|
Drug: Placebo drug
Inactive tablet Once a day Identical in appearance to intervention drug
|
Eligibility| Ages Eligible for Study: | 50 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria
All men over 50 to 80 and all women 55 to 80 who are resident in Kalaleh, Golestan, for at least one year.
Exclusion criteria
- Existing cardiovascular disease (stroke, transient ischaemic attack, myocardial infarction or angina)
- Already taking antihypertensive drugs, aspirin or statins
Already have clinical indications for treatment with antihypertensive drugs, aspirin or statins.
- Blood pressure >160/100 mm Hg
- Total Cholesterol > 240 mg/dL (or LDL >190 mg/dL)
- Probable diabetes: HbA1c >6.0
Contraindication to a component of the Polypill
Contraindications to aspirin
- Previous history of allergy to aspirin
- History of peptic ulcer bleeding in whole life or endoscopic evidence of peptic ulcer within the past 3 months
Contraindications to statins
- Liver failure Contraindications to further blood pressure lowering
- Systolic blood pressure ≤90 mm Hg or diastolic blood pressure ≤70 mm Hg
- Symptomatic postural hypotension
- Difference between mean seated BP and standing BP greater than 20 mm Hg
Contraindications to thiazide
- Uric acid >8 for men and uric acid >6 for women / gout (~10%)
- Creatinine >1.2 mg/dl
Other predominant medical problem that may limit compliance with study treatment including:
- History of alcohol abuse: more than 60cc for women and more than 80cc for men
- History of drug abuse: IV drug abuser or eating or smoking more than 4 times a week
- Limiting psychiatric illness (eg: mania, schizophrenia, severe depression, psychosis or dementia)
- Limiting physical disability sufficient to prevent subject from walking
- Other life-threatening condition such as cancer
Contacts and Locations| Iran, Islamic Republic of | |
| Kalaleh Heart Study Center | |
| Kalaleh, Golestan, Iran, Islamic Republic of | |
| Study Chair: | Reza Malekzadeh, M.D. | Tehran University of Medical Sciences |
| Principal Investigator: | Fatemeh Malekzadeh, M.D. | Tehran University of Medical Sciences |
| Principal Investigator: | Mansoor Rastegarpanah, Ph.D. | Tehran University of Medical Sciences |
| Study Chair: | Kar K Cheng, PhD | University of Birmingham |
| Principal Investigator: | Tom P Marshall, PhD | University of Birmingham |
| Study Director: | Akram Pourshams, PhD | Tehran University of Medical Sciences |
More Information
Publications:
| Responsible Party: | Reza Malekzadeh, Tehran University of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT00603590 History of Changes |
| Other Study ID Numbers: | 301/148, CCT-NAPN 15388 |
| Study First Received: | January 1, 2008 |
| Results First Received: | April 13, 2009 |
| Last Updated: | September 22, 2009 |
| Health Authority: | Iran: Ministry of Health |
Keywords provided by Tehran University of Medical Sciences:
|
Cardiovascular disease primary prevention Polypill efficacy safety |
ADR Diabetes Adherence Compliance |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Heart Diseases Hyperlipidemias Hypertension Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Vascular Diseases Hydrochlorothiazide Diuretics |
Natriuretic Agents Physiological Effects of Drugs Pharmacologic Actions Sodium Chloride Symporter Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Antihypertensive Agents Cardiovascular Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013